+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 76 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effect of pegloticase given by two different methods along with methotrexate in adults with uncontrolled gout. This phase 3 trial compares subcutaneous under the skin injections of pegloticase at 18 mg every two weeks with intravenous into a vein injections of pegloticase at 8 mg every two weeks, both combined with weekly methotrexate. The main goal is to see which approach better maintains low serum uric acid levels during the sixth month. Participants will be randomly assigned to receive either pegloticase by subcutaneous injection or by intravenous infusion, both administered every two weeks, alongside oral methotrexate taken weekly. The trial is double-blind, meaning neither participants nor researchers know which form of pegloticase is given. Methotrexate is given orally concurrently. Treatment continues through at least six months with ongoing evaluations. During the study, participants will have regular assessments to monitor their response to treatment, including blood tests to measure serum uric acid levels and pegloticase concentrations. Safety will be closely observed, including monitoring for injection site reactions, infusion reactions, and anaphylaxis up to 48 weeks. The primary outcome measures participants who maintain normalized uric acid levels during Month 6, with follow-up lasting up to 48 weeks. Total participation may extend to the study completion in June 2028.

Age: 18Years +All GendersPhase 3
75 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the effect of providing access to two types of heated tobacco products HTP on smoking reduction and abstinence among healthy adult smokers aged 21 to 65 years in the United States. This multi-site, open-label study aims to assess how using HTP devices with different flavored stick variants influences smokers ability to stop or reduce combustible cigarette use over a 3-month period. The primary goal is to measure the rate of complete cigarette abstinence in the final seven days of the study. Participants are randomly assigned to one of two study groups one using a one-piece HTP device and the other using a two-piece HTP device. Each device group includes access to four stick variantstwo menthol and two tobacco flavorsunder the brand name virto. The study includes a 90-day actual use period where participants try all four stick variants during a 1-week product trial and then continue use as they choose. The interventions are designed to explore the impact of these devices and flavors on cigarette smoking habits. Throughout the study, participants complete questionnaires via a smartphone app and undergo assessments related to cigarette use and product preferences. Researchers track cigarette reduction, switching to HTP use, time to abstinence, and adverse events over the 3-month period. The primary outcome is self-reported abstinence from combustible cigarettes in the last 7 days of the study. Secondary measures include reduction in cigarette use by at least 50%, complete switching to HTP, and safety monitoring. The total study duration spans up to 3 months with ongoing data collection and follow-up.

Age: 21Years - 65YearsAll GendersPhase Not Applicable
9 locations
E

Actively Recruiting

Researchers are evaluating PRT12396, an investigational oral drug, in adults with high-risk polycythemia vera PV and myelofibrosis MF, including primary MF and post-polycythemia vera or post-essential thrombocythemia MF with spleen enlargement. This first-in-human, open-label, multi-center Phase 1 study aims to assess the safety, tolerability, how the drug moves through the body, and preliminary effectiveness, while determining the maximum tolerated dose and recommended dose for future studies. The study has two parts first, a dose-escalation phase where participants receive increasing oral doses of PRT12396 twice daily to find the safest and best dose. Next, a dose-expansion phase enrolls more participants at the chosen dose to further study safety, tolerability, and early signs of effectiveness. Capsules are taken whole with water, either one hour before or two hours after meals. Participants will follow the treatment plan with regular visits for monitoring safety, blood tests, and drug levels over about two years. Researchers will track side effects, dose adjustments, blood counts, spleen size, symptom scores, and drug concentrations. The study aims to better understand the drugs effects, side effects, and appropriate dosing in these blood disorders.

Age: 18Years +All GendersPhase 1
22 locations
S

Actively Recruiting

Researchers are studying DB-1303BNT323, a biological drug, in a Phase 12a trial to evaluate its safety and tolerability in adults with advanced or metastatic malignant solid tumors that express HER2. The trial focuses on patients whose tumors are refractory to standard treatments or have no available standard options. This first-in-human study includes both a dose-escalation phase to find the maximum tolerated dose and a dose-expansion phase to further assess safety and explore efficacy in selected tumors. Participants receive DB-1303BNT323 intravenously once every three weeks at various dose levels, including a randomized comparison of doses during some expansion cohorts. Additional treatments may include ritonavir or itraconazole to assess drug interactions, and in some cases, DB-1303BNT323 is combined with Pertuzumab. The study is open-label and multicenter, with dosing continuing according to the protocols schedule. During the trial, participants undergo regular assessments including safety monitoring for adverse events, dose-limiting toxicities, and serious adverse events up to about one year post-treatment. Researchers measure tumor response using RECIST 1.1 criteria and evaluate pharmacokinetics and pharmacodynamics. Organ function, heart performance, and life expectancy are also monitored throughout this period. The estimated study completion is in October 2027.

Age: 18Years +All GendersPhase 1Phase 2
102 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of VS-7375, alone and combined with cetuximab or panitumumab, as well as cetuximab plus mFOLFOX chemotherapy, in patients with metastatic colorectal cancer that has a KRAS G12D mutation. This phase 2 study focuses on patients who have either not received prior treatment or have progressed after previous therapies. The goal is to understand how well these treatments work and how safe they are for this specific cancer type. Participants receive one of several treatment regimens VS-7375 alone or combined with cetuximab or panitumumab for patients with second-line or later metastatic colorectal cancer, or VS-7375 combined with cetuximab and mFOLFOX chemotherapy for patients newly diagnosed or with limited prior treatment. The study involves daily oral dosing of VS-7375 and intravenous infusions of the other drugs. Treatments are assigned randomly in a 21 ratio, and participants may cross over between treatments. Throughout the study, participants attend regular visits for evaluations including tumor assessments using RECIST criteria, safety and tolerability monitoring, blood tests for drug levels and tumor markers, and quality of life questionnaires. These assessments occur over periods ranging from 6 months to 2.5 years. The study measures confirmed tumor response rates and monitors for side effects to better understand the potential of these treatments for metastatic colorectal cancer. Participation may last until study completion in late 2028.

Age: 18Years +All GendersPhase 2
30 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of VS-7375, given alone and combined with cetuximab, in patients with metastatic non-small cell lung cancer NSCLC that have a specific KRAS G12D mutation. This phase 2 open-label study focuses on patients who have already received prior treatments and whose cancer has progressed. The goal is to better understand how this oral KRAS G12D inhibitor works in this advanced lung cancer setting. Participants will receive VS-7375 orally in one of several dosing regimens depending on their prior treatments and disease characteristics, including groups for second or third line 2L3L therapy and those with brain metastases receiving second to fourth line 2L-4L therapy. The study uses a randomized crossover design and will assess responses to treatment over time. Different doses may be provided, and participants may be monitored for disease progression and side effects during the treatment period. Throughout the trial, participants will have regular evaluations including imaging scans to measure tumor size according to RECIST criteria, safety assessments, blood tests for pharmacokinetics and pharmacodynamics, and quality of life questionnaires. The main outcomes include confirmed tumor response rates and safety over six months, with additional measures tracked up to 2.5 years. The study will also observe time to next therapy and health-related quality of life changes, with monitoring continuing through the planned study period until 2028.

Age: 18Years +All GendersPhase 2
24 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of VS-7375, an oral KRAS G12D ONOFF inhibitor, alone and combined with cetuximab in patients with metastatic pancreatic ductal adenocarcinoma PDAC that has the KRAS G12D mutation. This Phase 2, open-label study aims to understand how these treatments work in this specific patient group. The trial is sponsored by Verastem, Inc. and uses a randomized, parallel design.

Age: 18Years +All GendersPhase 2
38 locations
R

Actively Recruiting

Researchers are evaluating treatments for patients with accelerated or blast phase Philadelphia chromosome negative myeloproliferative neoplasms MPNs. This phase II trial compares ASTX727, a combination of cedazuridine and decitabine, given alone or combined with iadademstat. The study aims to assess how these treatments affect leukemia response rates and survival outcomes in patients who have not previously received certain DNA methyltransferase inhibitors. Patients are assigned to one of two groups. One group receives ASTX727 orally once daily on days 1 to 5 of each 28-day cycle. The other group receives the same ASTX727 schedule plus iadademstat orally on days 1-5, 8-12, 15-19, and 22-26 of each cycle. Treatment continues until disease progression or unacceptable side effects occur. Throughout the trial, researchers collect blood, buccal swab, and bone marrow samples to study the disease and treatment effects. Participants have regular assessments including blood tests, bone marrow biopsies, and sample collections over the treatment period. After stopping treatment for reasons other than disease progression, they are followed every 3 months if they stop due to progression, follow-up occurs every 6 months. The main outcome measured is the acute leukemia response rate within 4 treatment cycles. Secondary outcomes include event-free survival, overall survival, and the rate of stem cell transplantation over two years.

Age: 18Years +All GendersPhase 2
32 locations
C

Actively Recruiting

Researchers are comparing two treatment combinations for adults with advanced nonsquamous non-small cell lung cancer NSCLC that is stage IV or advanced stage IIIBC, specifically with a KRAS p.G12C mutation and no PD-L1 expression. The study evaluates progression-free survival and overall survival between participants receiving sotorasib with chemotherapy and those receiving pembrolizumab with chemotherapy. This is a phase 3, randomized, open-label study aiming to find which frontline therapy might better manage this type of lung cancer. Participants are randomly assigned to one of two groups one group receives sotorasib orally combined with carboplatin and pemetrexed chemotherapy, and the other group receives pembrolizumab given intravenously combined with the same chemotherapy agents. Treatments are given as front-line therapy for their cancer. The study measures the effects of these combinations over time, including tumor response and quality of life changes. During the study, participants will be closely monitored for progression-free survival, overall survival, and other outcomes related to tumor response and quality of life through questionnaires. Researchers will track treatment-emergent adverse events, vital signs, and lab tests to evaluate safety. The study includes follow-up assessments for up to approximately 5.5 years, allowing comprehensive evaluation of long-term outcomes and side effects. Participant involvement includes regular visits for treatment administration and assessments throughout the study period.

Age: 18Years - 100YearsAll GendersPhase 3
424 locations
S

Actively Recruiting

Researchers are evaluating the effects of experimental drugs pozelimab and cemdisiran in adults aged 50 to 85 with Geographic Atrophy GA caused by Age-related Macular Degeneration AMD, a condition affecting central vision. The study aims to compare the progression rate of GA in patients treated with cemdisiran alone, pozelimab combined with cemdisiran, and a placebo, while also examining side effects, drug levels in the blood, and immune responses to the drugs. Participants are randomly assigned to one of three groups pozelimab plus cemdisiran, cemdisiran alone, or placebo. All treatments are given by subcutaneous injection. The study is double-masked and placebo-controlled, lasting up to 104 weeks for key outcome measures, with extended safety monitoring up to 296 weeks. The trial includes multiple visits for evaluations and treatments over this period. During the study, participants undergo detailed eye imaging using Fundus Autofluorescence to measure GA lesion growth, assessments of visual acuity, and contrast sensitivity tests at weeks 52 and 104. Blood samples are collected to measure drug concentrations and immune responses, including antibodies against the drugs. Safety is monitored throughout the study and during extended follow-up. Participants adherence to clinic visits and vaccinations is required for participation.

Age: 50Years - 85YearsAll GendersPhase 3
231 locations

1-10 of 76

1